What is HC Wainwright’s Forecast for CAPR FY2024 Earnings?

Capricor Therapeutics Inc (NASDAQ:CAPR) – Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Capricor Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of ($1.33) for the year, up from their prior estimate of ($1.38). HC Wainwright currently has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.11) EPS.

Other research analysts have also issued reports about the stock. Oppenheimer reiterated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald raised their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler assumed coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Maxim Group raised their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Up 0.4 %

Shares of CAPR stock opened at $18.46 on Monday. The business’s 50 day moving average is $15.78 and its two-hundred day moving average is $8.68. Capricor Therapeutics has a 12 month low of $2.87 and a 12 month high of $23.40. The company has a market cap of $839.38 million, a PE ratio of -17.42 and a beta of 4.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics in the 1st quarter valued at $40,000. Main Street Financial Solutions LLC boosted its position in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in Capricor Therapeutics in the third quarter valued at about $133,000. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the second quarter worth about $147,000. Finally, The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics during the third quarter worth about $161,000. 21.68% of the stock is owned by institutional investors.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 12.00% of the stock is owned by corporate insiders.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.